Dr. Collins is an experienced R&D leader withextensive drug development and clinical expertise in central nervous system (CNS) disorders.
Prior to joining Bright Minds, Dr. Collins held several leadership positions at companies targeting CNS disorders, including as CEO of Biscayne Neurotherapeutics, a small molecule clinical stage company, and CEO and President of Biscayne Pharmaceuticals.
He served as CEO of Neurotherapeutics Pharma and Chief Scientific Officer & VP for Clinical Affairs of Ovation Pharmaceuticals, a CNS-focused biopharmaceutical company, wherethree anti-convulsant therapies, including Sabril for Infantile Spasms and Frisium for Lennox-Gastaut Syndrome, were developed and approved.
Prior to that, Dr. Collins served as a Global Director at Johnson & Johnson, overseeing early-stage development of a variety of CNS agents,and Abbott Laboratories’ Pharmaceutical and Hospital Products Divisions, where he developed drugs for a range of CNS indications, including Depakote, Depakote ER, Depacon, and Gabitril. He was responsible for all preclinical and clinical programs supporting the successful approval of multiple NDA and sNDA submissions.
Prior to industry, Dr. Collins served on the faculty of medicine at Case Western Reserve University and the University of California-San Francisco and was principal investigator or investigator on more than 40 drug and device trials.
